HC Wainwright Issues Pessimistic Estimate for EVAX Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – HC Wainwright reduced their FY2025 EPS estimates for shares of Evaxion Biotech A/S in a note issued to investors on Wednesday, April 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.03) per share for the year, down from their prior estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2026 earnings at ($0.02) EPS.

Separately, Lake Street Capital decreased their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th.

Evaxion Biotech A/S Trading Down 10.7 %

EVAX stock opened at $1.51 on Monday. The company has a fifty day moving average price of $2.30 and a two-hundred day moving average price of $6.68. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. The stock has a market cap of $1.77 million, a price-to-earnings ratio of -1.04 and a beta of -0.25. Evaxion Biotech A/S has a one year low of $1.50 and a one year high of $22.05.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings data on Tuesday, April 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.19. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.66 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Invst LLC lifted its holdings in Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,400 shares of the company’s stock after acquiring an additional 7,200 shares during the period. Invst LLC owned approximately 4.31% of Evaxion Biotech A/S worth $43,000 as of its most recent filing with the SEC. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.